Corbion is a Dutch company that specializes in food and biochemicals, with a history dating back to 1919. Corbion has a global presence, with offices and manufacturing facilities in the USA, Thailand, Brazil, Netherlands, Spain, and Mexico. Corbion's headquarters are located in Amsterdam, Netherlands. Corbion reported revenue of $1,457.9 million for FY 2022

Corbion's mission is to preserve what matters, using science to propel nature's ingenuity. Corbion offers sustainable solutions for the preservation of food and food production, health, and the planet. Corbion uses its unique expertise in fermentation and other processes to produce bioingredient-based foods, chemicals derived from organic acids, and lactic acid-based solutions for the food, chemical, and pharmaceutical industries.

Some of Corbion's products include bakery ingredients, meat ingredients, emulsifiers, functional blends, algae ingredients, lactic acid, lactides, polylactic acid (PLA), biobased succinic acid, and biobased 1,3-propanediol. Corbion serves markets such as food and beverage, home and personal care, animal nutrition, pharmaceuticals, medical devices, agriculture and horticulture, electronics, packaging, and textiles.

Corbion is also involved in various projects and awards that showcase its innovation and sustainability. For example, Corbion is a partner in the PEFerence project, which aims to establish an innovative value chain for the production of polyethylene furoate (PEF), a 100% biobased and recyclable polymer. Corbion also received the 2020 Fi Innovation Award for its Verdad® Opti Powder N70 ingredient, which is a natural mold inhibitor for bakery products.

Foundation: 1919
Headquarters: Amsterdam, Netherlands
Website: https://www.corbion.com/

Agendia is a company that specializes in precision oncology, which is the use of molecular diagnostics to guide personalized treatment decisions for cancer patients. Agendia was founded in 2003 as a spin-off from the Netherlands Cancer Institute and is headquartered in Irvine, California, with a European office in Amsterdam, Netherlands. Agenus Inc reported revenue of $57.9M for FY 2022.

Agendia's main product is MammaPrint, a 70-gene signature test that predicts the risk of recurrence and the benefit of chemotherapy for early-stage breast cancer patients. MammaPrint is the only test of its kind that has been validated by prospective randomized trials and is endorsed by international guidelines. Agendia also offers BluePrint, an 80-gene molecular subtyping test that identifies the functional subtype of breast cancer and helps to select the optimal targeted therapy.

Agendia is also involved in several research projects and collaborations to develop new tests and solutions for other types of cancer, such as colorectal, lung, prostate, and ovarian cancer. Agendia has received several awards and recognitions for its innovation and excellence, such as the Frost & Sullivan European Oncology Diagnostics Product Leadership Award in 2019 and the MedTech Breakthrough Award for Best Personalized Medicine Innovation in 2020.

Agendia's mission is to improve the quality of life and outcomes of cancer patients by providing them with actionable information that empowers them and their physicians to make the best treatment choices. Agendia believes that precision oncology is the future of cancer care and is committed to advancing the field with its cutting-edge technology and expertise.

Foundation: 2003
Headquarters: Amsterdam, Netherlands
Website: https://agendia.com/

Lumicks is a company based in the Netherlands that develops and sells innovative instruments for dynamic single-molecule and cell avidity analysis. The company was founded in 2014 as a spin-off from the Vrije Universiteit Amsterdam, where the core technology was developed by a team of physicists and biologists. LUMICKS has its headquarters in Amsterdam, where it also has its research and development, manufacturing, and sales departments. Lumicks also has offices in the United States, China, and India, and distributors in several other countries. Lumicks reported revenue of $43.7M for FY 2022.

Lumicks aims to advance science and improve human health by providing tools that unlock the measurement of forces and interactions in biology. Its instruments allow researchers to build the bridge between structure and function at both a molecular and a cellular level, by applying and measuring forces around biological interactions. This enables the detailed real-time analysis of underlying biological mechanisms, such as DNA repair, protein folding, cytoskeletal transport, phase separation, and immunotherapy.

Lumicks has received several awards and recognitions for its innovative technology and business achievements. In 2018, LUMICKS was named the National Icon of the Netherlands by the Ministry of Economic Affairs and Climate Policy. In 2019, LUMICKS won the Academic Enterprise Award (ACES) for Best Life Sciences Spin-out. In 2020, Lumicks raised €93 million in a Series D funding round led by Gilde Healthcare. In 2021, Lumicks became a public company listed on Euronext Amsterdam with a market capitalization of over €1 billion.

Foundation: 2014

Headquarters: Amsterdam, Netherlands.

Website: https://lumicks.com/

Mosa Meat was founded in 2013 by Professor Mark Post, a vascular biologist at Maastricht University, who created the world's first cultured beef burger in 2013. The burger cost $330,000 to produce and was funded by Google co-founder Sergey Brin. Since then, Mosa Meat has been working on scaling up the production process and reducing the cost of cultured meat. The company has raised over $85 million in funding from investors such as Merck Ventures, Nutreco, Bell Food Group, and Blue Horizon Ventures. Mosa Meat reported revenue of $35.2M for FY 2022.

Mosa Meat is based in Maastricht, Netherlands, where it has its headquarters and pilot production plant. The company plans to launch its first commercial product, a minced beef product, in 2022 in selected restaurants in Europe. Mosa Meat aims to achieve price parity with conventional beef by 2025 and to reach mass production by 2030. The company also hopes to expand its product portfolio to include other types of meat, such as steak and chicken.

Mosa Meat is not only a leader in cultured meat production, but also in research and innovation. The company has several ongoing projects and collaborations with academic and industry partners to improve the quality, safety, and sustainability of cultured meat.

Mosa Meat has received several awards and recognitions for its groundbreaking work in cultured meat. In 2018, the company won the World Technology Award for Environment from the World Technology Network. In 2019, the company was named one of the 50 Genius Companies by Time Magazine. In 2020, the company was ranked among the Top 100 Food Tech Companies by Forward Fooding.

Foundation: 2013

Headquarters: Maastricht, Netherlands

Website: https://mosameat.com/

Lava Therapeutics is a biotechnology company based in the Netherlands that is developing innovative therapies for cancer. The company was founded in 2016 by Dr. Hans van der Vliet, a leading expert in gamma delta T cell biology and immunotherapy. Lava Therapeutics reported revenue of US$19.4 million for FY 2022

Lava Therapeutics is on a mission to transform cancer therapy by harnessing the power of gamma delta T cells. The company believes that its Gammabody™ platform has the potential to provide durable immune responses and improve patient outcomes across multiple types of cancers.

Lava Therapeutics has a diverse pipeline of Gammabody™ candidates for different types of cancers, including solid tumors and hematological malignancies. The company's lead product, LAVA-051, is in phase 1/2a clinical trials for patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). LAVA-051 targets CD1d, a molecule that is expressed on both tumor cells and antigen-presenting cells, and can activate both gamma delta T cells and natural killer T (NKT) cells.

Lava Therapeutics has received several awards and recognitions for its innovative approach to cancer therapy. In 2020, the company was named one of the Fierce 15 biotech companies by Fierce Biotech, a leading industry publication. In 2021, the company completed a successful initial public offering (IPO) on the Nasdaq stock exchange, raising $100 million to advance its clinical development.

Foundation: 2016
Headquarters: Utrecht, Utrecht, Netherlands
Website: https://www.lavatherapeutics.com/

Avantium is a leading technology company in the field of renewable and sustainable chemistry. The company was founded in 2000 and is headquartered in Amsterdam, Netherlands. Avantium develops and commercializes innovative technologies for the production of plant-based chemicals and materials. Avantium reported revenue of €19.2 million for FY 2022. Avantium has a strong and diversified shareholder base, including Sofinnova Partners, RobecoSAM, Swedbank Robur, and Aster Capital.

One of Avantium's flagship technologies is the YXY technology, which enables the production of PEF, a 100% biobased and fully recyclable plastic with superior performance properties compared to today's widely used petroleum-based packaging materials. Avantium has partnered with major companies such as BASF, Coca-Cola, Danone, and ALPLA to bring PEF to the market.

Another promising technology developed by Avantium is the DAWN technology, which converts woody feedstock into industrial sugars and lignin. Lignin can be used for energy generation, but also for higher-value applications such as bio-asphalt. Avantium has recently constructed the world's first test road with lignin produced in the Netherlands, in collaboration with Roelofs and the province of Groningen.

Avantium's mission is to create disruptive technologies across entire value chains, bringing them to the world with partners to accelerate the transition towards more sustainable products. The company aims to make an impact by reducing greenhouse gas emissions, fossil fuel dependence, and plastic waste.

Foundation: 2000

Headquarters: Amsterdam, Netherlands

Website: https://www.avantium.com/

ISA Pharmaceuticals was founded in 2004 by Aglaia Oncology Fund and is based in Leiden Bio Science Park. The company has a strong scientific foundation and a proven track record of clinical development. ISA Pharmaceuticals has a diverse pipeline of SLP immunotherapies for various indications, such as cervical cancer, head and neck cancer, uveal melanoma, and COVID-19. ISA Pharmaceuticals reported revenue of $7.4 million for FY 2022

One of the most advanced products of ISA Pharmaceuticals is ISA101b, an SLP immunotherapy that targets human papillomavirus (HPV) type 16, which is responsible for about 70% of cervical cancers and 90% of oropharyngeal cancers. ISA101b has shown promising results in phase 2 clinical trials in combination with cemiplimab (Libtayo®), a PD-1 inhibitor, in patients with platinum-refractory HPV16 positive oropharyngeal cancer. The company has completed the enrolment of 150 patients in a randomized double-blind phase 2 trial and expects to report the results in 2023.

ISA Pharmaceuticals has received several awards and recognitions for its achievements and contributions to the field of immunotherapy. The company was awarded the Prix Galien Medtech Award in 2016 for its SLP technology. The company was also named one of the Top 10 Most Innovative Companies in Europe by Fast Company in 2017. Moreover, the company's co-founder and chief scientific officer, Prof. Cornelis Melief, was awarded the European Inventor Award in 2019 for his pioneering work on SLP immunotherapy.

Foundation: 2004

Headquarters: Leiden, South Holland, Netherlands.

Website: https://www.isa-pharma.com/

Leyden Labs was founded in 2020 by a team of world-renowned biotechnology veterans and fresh talent who are dedicated to freeing humanity from the burden of respiratory viruses. The company has raised $187.1 million in funding from investors such as F-Prime Capital and Bluebird Ventures. The company has also established offices and laboratories in Boston, MA, USA, and Granada, Spain. Leyden Labs reported revenue of $6.8 million for FY 2022.

Leyden Labs is currently developing two product candidates: PanFlu and PanCor. PanFlu is a nasal spray that contains an antibody called CR9114 that targets a common region of the influenza hemagglutinin protein. This antibody can neutralize all types of influenza viruses, including seasonal, pandemic, and avian strains. PanFlu is currently in Phase 1 clinical trials. PanCor is a nasal spray that contains an antibody called CR3022 that targets a common region of the coronavirus spike protein. This antibody can neutralize many types of coronaviruses, including SARS-CoV-2 and its variants. PanCor is expected to enter clinical trials in 2022.

Leyden Labs’ products have the potential to revolutionize the way we prevent and treat respiratory viral infections. They could offer a convenient, accessible, and universal solution that could empower people to live their lives to the fullest. Leyden Labs’ vision is to protect humanity from what comes next.

Foundation: 2020
Headquarters: Amsterdam, Noord-Holland, Netherlands

Website: https://leydenlabs.com

NorthSea Therapeutics was founded in 2017 by a group of experienced biotech entrepreneurs and scientists with a track record of success in developing and commercializing innovative therapies for metabolic and liver diseases. The company has raised over $200 million in funding from leading life science investors, including Forbion, Novo Holdings, venBio Partners, Sofinnova Investments, and New Science Ventures. NorthSea Therapeutics reported revenue of $5M for FY 2022.

The lead product candidate of NorthSea Therapeutics is icosabutate, a once-daily, oral SEFA that is currently in a Phase 2b clinical trial for the treatment of NASH, a chronic liver disease that affects millions of people worldwide, and has no approved therapies. NASH is characterized by fat accumulation, inflammation, and fibrosis in the liver, which can lead to cirrhosis, liver failure, and liver cancer. Icosabutate has shown promising results in a pre-specified interim analysis of Phase 2b trial, demonstrating significant improvements in liver function parameters, inflammatory and fibrotic biomarkers, lipid profile, and glycemic control. Icosabutate has also been well-tolerated, with no serious safety signals to date. The final data from the Phase 2b trial are expected in Q1 2023.

NorthSea Therapeutics has received several awards and recognitions for its innovative approach and achievements. In 2019, the company won the BioCapital Europe Award for Best Company Presentation. In 2020, the company was selected as one of the Fierce 15 Biotech Companies of the Year by Fierce Biotech. In 2021, the company was named as one of the Top 20 Biotech Startups to Watch by Labiotech.eu.

Foundation: 2017

Headquarters: Naarden, Noord-Holland, The Netherlands.

Website: https://www.northseatherapeutics.com/

CimCure was founded in 2015 by its CSO, Prof. Arjan Griffioen, who is a world-renowned expert in angiogenesis, the process of blood vessel formation. CimCure is a spin-off company of Amsterdam UMC, one of the largest academic medical centers in the Netherlands. CimCure has a strong scientific team with extensive experience in immunology, pharmacology, and oncology.

CimCure's lead product is CimVax-001, a conjugate vaccine that consists of a tumor vascular antigen (TVA) linked to a carrier protein. CimVax-001 has shown promising results in preclinical studies, demonstrating potent anti-tumor and anti-metastatic effects in various animal models. CimVax-001 is currently in phase I clinical trials in patients with advanced solid tumors.

CimCure has also developed a platform technology that allows the rapid identification and validation of novel TVAs for different types of cancer. This technology enables CimCure to create a pipeline of customized cancer vaccines for various indications and patient populations.

CimCure has received several awards and grants for its innovative technology and product development. In 2018, CimCure won the prestigious Amsterdam Science & Innovation Award for its breakthrough approach to cancer immunotherapy. In 2019, CimCure received a €2.5 million grant from the European Union's Horizon 2020 program to support the clinical development of CimVax-001.

Foundation: 2015
Headquarters: Amsterdam, Netherlands
Website: https://cimcure.com/